Erem H H, Kiran R P, Remzi F H, Vogel J D
Department of Colorectal Surgery, Digestive Disease Institute, Cleveland Clinic, Cleveland, OH, USA,
Tech Coloproctol. 2014 Aug;18(8):719-24. doi: 10.1007/s10151-014-1129-9. Epub 2014 Feb 22.
The Surgical Care Improvement Project (SCIP) includes recommendations for mechanical and pharmacologic venous thromboembolism (VTE) prophylaxis after colorectal surgery. Compliance with these recommendations is publicly reported and included in current pay for performance plans. Presently, there is limited evidence to support compliance with these recommendations.
To determine the incidence of venous thromboembolic events in colorectal surgery patients who did or did not receive the recommended pharmacologic prophylaxis.
We performed a retrospective analysis of prospectively accrued data from a single-center, tertiary care, colorectal surgery department. The main outcome measure was the occurrence of venous thromboembolic events and the need for blood transfusion after surgery.
Of 674 patients, 613(91%) received the recommended pharmacologic VTE prophylaxis and 61 (9%) did not. Diagnosis, patient variables, and type of surgery performed were similar in each group while operative time was increased in the compliant group (251 vs. 194 min, p < 0.05). In the compliant and noncompliant groups, the incidence of extremity deep venous thrombosis was 2.8 and 8.2% (p = 0.04), the incidence of pulmonary embolus 1.1 and 3.3% (p = 0.19), the incidence of portomesenteric venous thrombosis 2.6 and 4.9% (p = 0.38), and the incidence of any VTE 5.4 and 13.1% (p = 0.02), respectively. The use of perioperative red blood cell transfusions in the two groups was 9.1 and 14.8%, p = 0.17. In the subgroup analysis of open cases, there were no statistical differences in the occurrence of any type or combination of VTE.
Compliance with SCIP recommendations for pharmacologic VTE prophylaxis decreased the incidence of VTE after colorectal surgery with no increase in the use of perioperative transfusion. Colorectal surgeons who elect to skip these recommendations may jeopardize both the reputational score and financial reimbursement of their hospital and may put their patients at unnecessary risk for a preventable postoperative complication.
外科护理改进项目(SCIP)包括结直肠手术后机械性和药物性静脉血栓栓塞(VTE)预防的建议。对这些建议的依从性会公开报告,并纳入当前的绩效薪酬计划。目前,支持遵循这些建议的证据有限。
确定接受或未接受推荐药物预防的结直肠手术患者静脉血栓栓塞事件的发生率。
我们对来自单中心三级护理结直肠外科前瞻性收集的数据进行了回顾性分析。主要结局指标是静脉血栓栓塞事件的发生情况以及术后输血需求。
674例患者中,613例(91%)接受了推荐的药物性VTE预防,61例(9%)未接受。两组的诊断、患者变量和手术类型相似,但依从组的手术时间延长(251分钟对194分钟,p<0.05)。在依从组和非依从组中,肢体深静脉血栓形成的发生率分别为2.8%和8.2%(p=0.04),肺栓塞的发生率分别为1.1%和3.3%(p=0.19),门静脉肠系膜静脉血栓形成的发生率分别为2.6%和4.9%(p=0.38),任何VTE的发生率分别为5.4%和13.1%(p=0.02)。两组围手术期红细胞输血的使用率分别为9.1%和14.8%,p=0.17。在开放手术病例的亚组分析中任何类型或VTE组合的发生情况无统计学差异。
遵循SCIP关于药物性VTE预防的建议可降低结直肠手术后VTE的发生率,且围手术期输血使用率未增加。选择不遵循这些建议的结直肠外科医生可能会损害其医院的声誉评分和财务报销,并可能使患者面临可预防的术后并发症的不必要风险。